• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: TERUMO BCT SPECTRA OPTIA; SPECTRA OPTIA COLLECT SET

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

TERUMO BCT SPECTRA OPTIA; SPECTRA OPTIA COLLECT SET Back to Search Results
Catalog Number 4121201
Device Problem Insufficient Information (3190)
Patient Problem Insufficient Information (4580)
Event Date 05/28/2023
Event Type  Injury  
Event Description
Per journal article "characteristics of autologous peripheral blood stem cells collection over a one-year period" by ahmetovic-karic, et alahmetovic-karic, g., catovic-baralija, e., sofo-hafizovic, a.A retrograde analysis of 24 leukapheresis in 20 adult patients with malignant hematological diseases in the blood transfusion institute of the federation of bosnia and herzegovina in sarajevo, was done.Cell separators amicus and spectra optia were used for collection procedures.Results the patient¿s age ranged from 27 to 65 years.Target cells were collected in one procedure in sixteen patients, while in four patients they were collected in two procedures.The mean cd34+ collection efficiency was (b)(4).The median number of cd34+ cells and percentage of cd34+ cells in the products were 5.52x10e6/kg (range (b)(4)) and (b)(4) (range (b)(4)).A strong positive correlation was found between the number of cd34+ cells in peripheral blood on the apheresis day and the amount of cd34+ cells collected in the products ((b)(4)).A total of (b)(4) of patients collected the amount of =3x10e6/kg and (b)(4) of =5x10e6/kg cd34+ cells for a single transplant.A decrease in platelet count, hemoglobin and hematocrit values after the procedure was not significant.Potassium decrease showed statistical significance ((b)(4)).Adverse events occurred during one procedure (b)(4).A decrease in platelet count, haemoglobin and haematocrit values in peripheral blood after leukapheresis was observed, without statistical significance ((b)(4), respectively).The median number of circulating cd34+ cells in peripheral blood on apheresis day was 62x10e6/l (range (b)(4)).Calcium and potassium values in peripheral blood decreased after the procedure, where the decrease in potassium showed statistical significance ((b)(4)) (table 4).Adverse events occurred during one procedure ((b)(4)) due to impaired blood flow through one of the lines of central venous catheter.Specific details, such as patient information and outcome, were not included in the article for these events, therefore this report is being provided as a summary of the events.It is unknown at this time if medical intervention was required for these events the collection set is not available for return because it was discarded by the customer.
 
Manufacturer Narrative
Lot number, manufacture and expiry date are not available at this time.Investigation: per the article "in conclusion, the leukapheresis procedure is fully automated and involves the use of standardized cell collection protocols.The results of this study, such as low number of adverse events and good collection efficiency with adequate patient monitoring, indicate that leukapheresis is a safe procedure that is successfully used in the autologous transplantation process in the treatment of malignant haematological diseases." investigation is in process, a follow-up report will be provided.Citation: ahmetovic-karic, g., catovic-baralija, e., & sofo-hafizovic, a.(2020).Characteristics of autologous peripheral blood stem cells collection over a one-year period.Medicinski glasnik: official publication of the medical association of zenica-doboj canton, bosnia and herzegovina, 17(2), 290¿296.Https://doi.Org/10.17392/1171-20.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
SPECTRA OPTIA
Type of Device
SPECTRA OPTIA COLLECT SET
Manufacturer (Section D)
TERUMO BCT
lakewood CO 80215
Manufacturer (Section G)
TERUMO BCT
10810 w. collins ave
lakewood CO 80215
Manufacturer Contact
scot hilden
10810 w. collins ave
lakewood, CO 80215
MDR Report Key18951290
MDR Text Key338307647
Report Number1722028-2024-00087
Device Sequence Number1
Product Code LKN
UDI-Device Identifier05020583121201
UDI-Public05020583121201
Combination Product (y/n)N
Reporter Country CodeBK
PMA/PMN Number
K183081
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Health Professional
Reporter Occupation Other Health Care Professional
Type of Report Initial
Report Date 03/21/2024
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received03/21/2024
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Catalogue Number4121201
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received02/26/2024
Was Device Evaluated by Manufacturer? No
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Other;
-
-